develop
polynucleotid
technolog
therapeut
agent
led
food
drug
administr
fda
approv
formivirsen
phosphothio
cytomegaloviru
retin
acquir
immun
defici
syndrom
patient
give
hope
drug
similar
mechan
action
would
also
approv
unfortun
ensu
year
disappoint
regard
nevertheless
advent
rnai
number
activ
clinic
trial
therapeut
oligonucleotid
grown
enorm
accord
estim
therapeut
target
druggabl
small
molecul
therapi
make
rnai
mediat
attract
unlik
tradit
small
drug
approach
gene
cell
type
tissu
potenti
target
rnai
mediat
deliveri
major
limit
march
opko
health
inc
announc
decid
termin
first
phase
iii
clinic
studi
treatment
wet
amd
recommend
independ
data
monitor
committe
includ
tabl
reason
report
last
year
univers
kentucki
suggest
bevasiranib
suppress
blood
vessel
format
activ
immun
receptor
suggest
drug
effect
may
nonspecif
despit
sever
compani
still
activ
progress
rnai
technolog
clinic
trial
current
rnai
mediat
drug
develop
preclin
trial
phase
clinic
trial
phase
ii
clinic
trial
phase
iii
clinic
trial
synthet
nucleic
acid
tabl
show
list
compani
activ
rnai
mediat
drug
program
clinic
trial
review
known
compani
effort
includ
alnylam
calando
santari
alnylam
sirna
rsv
enter
phase
ii
clinic
trial
preliminari
report
promis
alnylam
rnai
therapeut
design
target
conserv
n
gene
rsv
genom
critic
replic
viru
sinc
initi
therapeut
program
alnylam
made
rapid
progress
alnylam
licens
intellectu
properti
univers
south
cover
rnai
composit
method
treat
pulmonari
viral
infect
sirna
compani
also
form
exclus
allianc
kyowa
hakko
develop
commerci
japan
major
market
asia
februari
alnylam
announc
achiev
human
proof
concept
first
industri
result
compani
gemini
trial
show
statist
signific
antivir
efficaci
gemini
random
phase
ii
trial
healthi
adult
volunt
experiment
inocul
rsv
intranas
administ
day
day
day
prior
day
follow
viral
infect
gave
reduct
infect
rate
measur
plaqu
assay
similar
signific
reduct
measur
polymeras
chain
reaction
pcr
cultur
rsv
antigen
assay
increas
number
patient
remain
free
infect
vs
placebo
viral
load
peak
viral
load
durat
viral
shed
mean
daili
viral
load
show
consist
trend
favor
treatment
effect
signific
differ
clinic
symptom
safe
well
toler
april
alnylam
initi
phase
ii
clinic
trial
assess
safeti
toler
aerosol
versu
placebo
adult
lung
transplant
patient
natur
infect
rsv
receiv
drug
administ
inhal
via
nebul
expect
deliveri
formul
commerci
secondari
object
trial
first
evalu
antivir
activ
natur
acquir
rsv
lower
respiratori
tract
infect
alnylam
also
activ
advanc
rnai
therapeut
treatment
solid
tumor
liver
involv
target
two
key
gene
involv
diseas
pathway
liver
cancer
kinesin
spindl
protein
ksp
vegf
thought
approach
increas
potenti
signific
therapeut
benefit
cancer
treatment
preclin
studi
demonstr
abil
silenc
tumor
ksp
vegf
stop
prolifer
cancer
cell
studi
show
strike
reduct
growth
number
signific
tumor
mass
liver
data
report
annual
meet
intern
societi
biolog
therapi
cancer
demonstr
robust
efficaci
orthotop
liver
tumor
model
includ
inhibit
tumor
growth
measur
serum
level
afp
signific
surviv
benefit
specif
silenc
ksp
vegf
demonstr
rnai
mechan
action
toward
target
gene
mrna
confirm
late
investig
new
drug
ind
applic
submit
us
fda
accept
phase
clinic
trial
titl
dose
escal
trial
evalu
safeti
toler
pharmacokinet
intraven
patient
advanc
solid
tumor
liver
involv
enrol
estim
peopl
http
wwwcancergovdrugdictionari
june
calando
pharmaceut
dose
first
patient
nanoparticl
sirna
silenc
subunit
ribonucleotid
medic
consist
four
compon
includ
synthet
nonchem
modifi
sirna
cyclodextran
polym
stabil
agent
target
agent
form
approxim
nm
particl
target
agent
contain
human
transferrin
protein
cation
polym
cyclodextran
interact
electrostat
anion
sirna
assembl
nanocomplex
approxim
nm
diamet
protect
sirna
nucleas
degrad
serum
nanocomplex
target
cell
tfr
upon
reach
target
cell
transferrin
bind
tfr
cell
surfac
nanocomplex
enter
cell
endocytosi
insid
cell
chemistri
built
polym
achiev
unpackag
sirna
nanocomplex
permit
function
via
rna
agent
termin
adamantan
group
form
inclus
complex
cyclodextrin
contain
polyethylen
glycol
peg
endow
particl
properti
prevent
aggreg
enhanc
stabil
enabl
system
administr
ligand
cell
surfac
receptor
coval
attach
modifi
enabl
particl
target
tissu
interest
worker
caltech
children
hospit
locat
lo
angel
also
use
nanoparticl
made
calando
deliveri
system
sirna
fusion
gene
prevent
tumor
growth
dissemin
murin
model
ewe
treatment
made
use
femal
diabeticsever
combin
immunodefici
nodscid
mice
inject
human
ewe
sarcoma
cell
sirna
dose
mgkg
dose
administ
weekli
twice
week
treatment
group
contain
mice
safeti
evalu
ongo
well
addit
efficaci
studi
anim
model
pleas
refer
list
public
inform
therapeut
microrna
preclin
stage
santari
recent
began
clinic
trial
molecul
treatment
viru
santari
use
interspers
lock
nucleic
acid
combin
along
phosphorothio
backbon
act
sequest
mirna
despit
opportun
numer
challeng
drug
would
overcom
everi
mirna
target
multipl
gene
influenc
ten
hundr
biolog
pathway
number
safeti
concern
address
signific
anoth
issu
choos
right
mirna
target
recent
grow
bodi
evid
suggest
link
mirna
profil
cell
oncogen
potenti
lucid
pictur
role
mirna
play
cancer
like
come
forward
effort
examin
cancer
genom
reveal
number
mutat
mirna
gene
target
sequenc
conjug
sirna
molecul
target
molecul
promis
mean
conjug
usual
form
coval
attach
target
molecul
passeng
strand
rnai
mediat
disrupt
silenc
activ
conjug
attract
approach
wide
varieti
potenti
target
moieti
includ
nucleic
acid
peptid
aptam
cell
permeabl
peptid
antibodi
natur
molecul
cholesterol
would
expect
low
sirna
deliveri
activ
area
investig
immunoliposom
approach
liposom
chemic
coupl
antibodi
form
inject
complex
bind
surfac
antigen
liposom
fuse
cell
membran
deliv
sirna
cell
altern
approach
use
modifi
protein
distinct
theori
protein
complex
inject
anim
bind
target
cell
subsequ
intern
endocytosi
rnai
mediat
dissoci
target
deliveri
vehicl
exit
endosom
enter
cytoplasm
enter
rnai
silenc
protein
complex
use
induc
gene
take
place
fine
balanc
sirna
affin
carrier
need
sirna
releas
upon
enter
endosom
current
effort
sirna
deliveri
classifi
three
categori
immunoliposom
recombin
antibodi
fusion
conjug
target
transport
technolog
describ
recombin
fusion
immunoconjug
distinct
domain
fuse
one
protein
unit
prior
deliveri
rnai
mediat
mix
form
complex
domain
fusion
complex
complex
form
inject
anim
model
bind
target
cell
subsequ
endocytosi
sirna
dissoci
interact
silenc
complex
risc
research
paper
song
colleagu
gene
encod
nucleic
acid
bind
protein
fuse
gene
encod
fab
fragment
antibodi
direct
human
immunodefici
viru
hiv
env
protein
fusion
protein
load
sirna
use
select
deliv
sirna
cell
express
env
gene
recombin
fusion
deliv
sirna
cell
express
integrin
lymphocyt
function
associ
also
shown
efficaci
use
singl
chain
antibodi
specif
fuse
shankar
group
demonstr
cell
specif
sirna
deliveri
effect
inhibit
hiv
use
antivir
report
demonstr
promis
direct
sirna
deliveri
specif
blood
great
deal
excit
progress
toward
vivo
deliveri
achiev
use
recombin
immunoconjug
approach
develop
still
sever
barrier
limit
develop
small
size
domain
limit
amount
sirna
associ
process
produc
recombin
modifi
antibodi
fusion
often
provid
low
yield
desir
product
recombin
product
process
difficult
elimin
requir
denaturationrefold
step
would
improv
product
effici
scalabl
releas
function
sirna
antibodi
lack
control
vivo
sirna
deliveri
efficaci
immunoconjug
test
system
inject
nodscid
mice
silenc
glyceraldehyd
dehydrogenas
gapdh
express
tumor
cell
target
antigen
perform
anim
test
use
antibodi
conjug
tumor
made
cell
line
express
breast
cancer
cell
line
contain
significantli
low
level
receptor
nodscid
mice
inject
subcutan
either
million
cell
flank
monitor
postinject
tumor
format
tumor
reach
suffici
size
sirna
treatment
use
antibodi
conjug
deliveri
vehicl
commenc
mix
antibodi
conjug
either
gapdh
sirna
sirna
inject
tumor
twice
interv
inject
hour
follow
inject
mice
sacrif
tumor
remov
process
analyz
knockdown
use
gapdh
immunosorb
assay
elisa
data
illustr
figur
suggest
antibodi
conjug
may
deliv
sirna
load
knockdown
gapdh
cell
express
effect
use
rnai
mediat
therapi
current
depend
avail
deliveri
vehicl
system
administ
target
particular
cell
limit
side
effect
nake
rnai
mediat
deliv
bloodstream
order
minut
renal
addit
serum
nucleas
recogn
doubl
strand
rna
serum
rnase
degrad
sirna
overcom
challeng
rnai
mediat
mix
liposom
peptid
target
iv
deliveri
anim
model
cancer
work
effect
system
yet
target
sirna
deliveri
system
follow
characterist
rnai
mediat
must
protect
blood
stream
prolong
transport
must
occur
across
endotheli
wall
must
specif
bind
cell
plasma
membran
activ
endocytosi
cell
rnai
mediat
must
activ
target
cell
elicit
desir
biolog
respons
current
avail
rnai
mediat
deliveri
technolog
espous
characterist
sever
studi
come
close
develop
tumor
select
deliveri
system
schiffel
et
attach
acid
rgd
peptid
ligand
distal
end
peg
mean
target
tumor
integrin
pegyl
polyethyleneimin
pei
complex
sirna
tail
vein
inject
mice
show
select
uptak
inhibit
tumor
angiogenesi
growth
rate
complex
shown
improv
serum
stabil
h
compar
unformul
rnai
mediat
use
similar
approach
kim
et
util
deliv
sirna
target
green
fluoresc
protein
gfp
folat
receptor
tumor
cell
line
kb
cell
result
demonstr
success
target
reduct
cytoplasm
build
premis
rnai
mediat
deliveri
peer
et
develop
liposom
base
sirna
vehicl
target
specif
leukocyt
subset
gut
inflamm
use
stabil
unilamellar
vesicl
ulv
coval
attach
hyaluronan
palmitoylphosphatidylethanolamin
dppe
ulv
stabil
particl
system
circul
endocytosi
monoclon
antibodi
integrin
coval
attach
hyaluronan
system
applic
silenc
leukocyt
revers
induc
coliti
mice
suppress
leukocyt
prolifer
helper
cell
cytokin
express
coval
conjug
perform
peer
et
al
typic
perform
reactiv
site
carri
head
group
phospholipid
use
crosslink
intermediari
conjug
may
perform
crosslink
reagent
carbodiimid
reduct
amin
nh
ester
activ
carboxyl
use
interact
stabil
vivo
use
complex
often
depend
size
liposom
particl
amount
antibodi
reaction
mole
amount
lipid
bilay
formul
use
conjug
demonstr
pirollo
et
specif
deliv
sirna
primari
metastat
tumor
includ
prostat
pancreat
breast
tumor
system
administr
pirollo
et
al
util
complex
deliv
sirna
liposom
encapsul
sirna
cation
dotap
dioleoyl
phosphatidylethanolamin
dope
lipid
label
target
moieti
tfr
level
shown
correl
prolif
natur
tumor
cell
recycl
intern
rapidli
divid
cancer
contribut
uptak
liposom
complex
sirna
reach
intend
target
must
releas
endosom
knockdown
gene
interest
often
limit
efficaci
mani
studi
incorpor
ph
sensit
compon
liposom
develop
tri
enhanc
effici
liposom
payload
exploit
fact
endosom
compart
gener
acid
natur
destabil
target
liposom
follow
acidif
enhanc
inclus
dope
undergo
lamellar
hexagon
phase
transit
low
ph
releas
captur
liposom
compon
ph
sensit
peptid
attach
liposom
neutral
ph
bind
adjac
bilay
acid
ph
util
latter
approach
chen
et
aoki
et
develop
polym
shown
disrupt
endosom
increas
transfect
effici
unmodifi
cation
liposom
use
liposom
contain
sirna
label
polym
adapt
studi
pirollo
et
demonstr
tumor
specif
deliveri
result
knockdown
express
tumor
show
size
reduct
xenograft
tumor
use
technolog
field
sirna
like
rapid
progress
technolog
propel
vitro
cell
cultur
studi
advanc
clinic
trial
year
data
preclin
program
suggest
sirna
therapeut
potenti
treat
diseas
mani
preclin
studi
led
ongo
clinic
trial
encourag
preliminari
result
despit
progress
deliveri
remain
largest
obstacl
improv
sirna
therapi
understand
therapi
deliv
tissu
affect
diseas
essenti
wide
success
treat
diseas
current
clinic
trial
util
direct
inject
organ
target
administr
unmodifi
sirna
sirna
minor
chemic
modif
direct
inject
target
administr
remain
best
option
sirna
deliveri
today
unlik
therapeut
limit
approach
broad
yet
target
system
clinic
treatment
like
futur
safe
efficaci
human
applic
move
direct
multipl
deliveri
technolog
requir
evolv
base
uniqu
challeng
organ
diseas
may
pose
propos
deliveri
vehicl
lead
way
direct
sirna
target
assumpt
base
previou
success
obtain
use
antibodi
treat
diseas
practic
standpoint
antibodi
design
target
cellular
surfac
antigen
specif
fashion
antibodi
also
engin
impact
immun
system
human
antibodi
drug
conjug
mylotarg
alreadi
approv
fda
use
treat
human
diseas
factor
well
other
make
method
drug
deliveri
attract
